These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 38396769)
1. Inhibitors of NAD Ghanem MS; Caffa I; Monacelli F; Nencioni A Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396769 [TBL] [Abstract][Full Text] [Related]
2. Advances in NAD-Lowering Agents for Cancer Treatment. Ghanem MS; Monacelli F; Nencioni A Nutrients; 2021 May; 13(5):. PubMed ID: 34068917 [TBL] [Abstract][Full Text] [Related]
3. A Versatile Continuous Fluorometric Enzymatic Assay for Targeting Nicotinate Phosphoribosyltransferase. Minazzato G; Marangoni E; Fortunato C; Petrelli R; Cappellacci L; Del Bello F; Sorci L; Gasparrini M; Piacente F; Bruzzone S; Raffaelli N Molecules; 2023 Jan; 28(3):. PubMed ID: 36770640 [TBL] [Abstract][Full Text] [Related]
4. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models. O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854 [TBL] [Abstract][Full Text] [Related]
5. Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair. Piacente F; Caffa I; Ravera S; Sociali G; Passalacqua M; Vellone VG; Becherini P; Reverberi D; Monacelli F; Ballestrero A; Odetti P; Cagnetta A; Cea M; Nahimana A; Duchosal M; Bruzzone S; Nencioni A Cancer Res; 2017 Jul; 77(14):3857-3869. PubMed ID: 28507103 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review. Gasparrini M; Giovannuzzi S; Nocentini A; Raffaelli N; Supuran CT Expert Opin Ther Pat; 2024 Jul; 34(7):565-582. PubMed ID: 38861278 [TBL] [Abstract][Full Text] [Related]
7. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities. Chen H; Wang S; Zhang H; Nice EC; Huang C Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719 [TBL] [Abstract][Full Text] [Related]
8. Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery. Ghanem MS; Caffa I; Del Rio A; Franco J; Parenti MD; Monacelli F; Cea M; Khalifa A; Nahimana A; Duchosal MA; Ravera S; Bertola N; Bruzzone S; Nencioni A; Piacente F Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890147 [TBL] [Abstract][Full Text] [Related]
9. Dual-targeted NAMPT inhibitors as a progressive strategy for cancer therapy. Ozgencil F; Gunindi HB; Eren G Bioorg Chem; 2024 Aug; 149():107509. PubMed ID: 38824699 [TBL] [Abstract][Full Text] [Related]
10. Drug discovery targeting nicotinamide phosphoribosyltransferase (NAMPT): Updated progress and perspectives. Wen F; Gui G; Wang X; Ye L; Qin A; Zhou C; Zha X Bioorg Med Chem; 2024 Feb; 99():117595. PubMed ID: 38244254 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress. Sharma P; Xu J; Williams K; Easley M; Elder JB; Lonser R; Lang FF; Lapalombella R; Sampath D; Puduvalli VK Neuro Oncol; 2022 Feb; 24(2):229-244. PubMed ID: 34260721 [TBL] [Abstract][Full Text] [Related]
12. Identification of the Nicotinamide Salvage Pathway as a New Toxification Route for Antimetabolites. Buonvicino D; Mazzola F; Zamporlini F; Resta F; Ranieri G; Camaioni E; Muzzi M; Zecchi R; Pieraccini G; Dölle C; Calamante M; Bartolucci G; Ziegler M; Stecca B; Raffaelli N; Chiarugi A Cell Chem Biol; 2018 Apr; 25(4):471-482.e7. PubMed ID: 29478906 [TBL] [Abstract][Full Text] [Related]
13. Discovery of a novel nicotinamide phosphoribosyl transferase (NAMPT) inhibitor via in silico screening. Takeuchi M; Niimi T; Masumoto M; Orita M; Yokota H; Yamamoto T Biol Pharm Bull; 2014; 37(1):31-6. PubMed ID: 24389478 [TBL] [Abstract][Full Text] [Related]
14. Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience. Montecucco F; Cea M; Bauer I; Soncini D; Caffa I; Lasigliè D; Nahimana A; Uccelli A; Bruzzone S; Nencioni A Curr Drug Targets; 2013 Jun; 14(6):637-43. PubMed ID: 23531116 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer. Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells. Tan B; Dong S; Shepard RL; Kays L; Roth KD; Geeganage S; Kuo MS; Zhao G J Biol Chem; 2015 Jun; 290(25):15812-15824. PubMed ID: 25944913 [TBL] [Abstract][Full Text] [Related]
17. Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors. Duarte-Pereira S; Pereira-Castro I; Silva SS; Correia MG; Neto C; da Costa LT; Amorim A; Silva RM Oncotarget; 2016 Jan; 7(2):1973-83. PubMed ID: 26675378 [TBL] [Abstract][Full Text] [Related]
18. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Hasmann M; Schemainda I Cancer Res; 2003 Nov; 63(21):7436-42. PubMed ID: 14612543 [TBL] [Abstract][Full Text] [Related]
19. Bacteria Boost Mammalian Host NAD Metabolism by Engaging the Deamidated Biosynthesis Pathway. Shats I; Williams JG; Liu J; Makarov MV; Wu X; Lih FB; Deterding LJ; Lim C; Xu X; Randall TA; Lee E; Li W; Fan W; Li JL; Sokolsky M; Kabanov AV; Li L; Migaud ME; Locasale JW; Li X Cell Metab; 2020 Mar; 31(3):564-579.e7. PubMed ID: 32130883 [TBL] [Abstract][Full Text] [Related]
20. Mechanism of Allosteric Modulation of Nicotinamide Phosphoribosyltransferase to Elevate Cellular NAD Ratia KM; Shen Z; Gordon-Blake J; Lee H; Laham MS; Krider IS; Christie N; Ackerman-Berrier M; Penton C; Knowles NG; Musku SR; Fu J; Velma GR; Xiong R; Thatcher GRJ Biochemistry; 2023 Feb; 62(4):923-933. PubMed ID: 36746631 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]